Business
Business
Latest Headlines
Top Stories
Breaking News
Earnings
Biotech
Investors
Stock Alerts
IPOs
M&A
Canadian
UK
Wallstreet Events
Industry News
Industry News
Technology
Software
Banking
Automotive
Energy
More
Corp. Calendars
Dividends
Stock Splits
Buybacks
Conference Calls
Earnings Calendar
Earnings Calendar
Pos Pre-announcements
Profit Warnings
Positive Surprise
Negative Surprise
Latest Earnings
FDA Calendars
Drug Approvals
Clinical Trial Calendar
Ratings Changes
Upgrades
Downgrades
Cov Initiations
Cov. Reiterated
Economy
Economic News
US
Europe
Asia
Global
Economic Calendar
Economic Scorecard
Cryptocurrency
Crypto
Cryptocurrency
Blockchain
Markets
Markets
Morning Mkt Analysis
US Commentary
European Commentary
Asian Commentary
Canadian Commentary
Indian Commentary
Commodities
Bonds
Currencies
Politics
Politics
US
World
White House
Elections
General News
Forex
Forex
FX Top Stories
Currency Analysis
Currency Alerts
Economic Calendar
Economic Scorecard
Health
Health
Coronavirus
COVID-19 Calendar
Diet & Fitness
Cannabis
Kids Health
Men's Health
Women's Health
Cancer News
Drug Development
Mental Health
Slide Shows
Entertainment
Entertainment
Top Stories
Music news
Pop
Rock
Classic Rock
Rap/Hip-Hop
Country
Alternative
Oldies
All Genre
Content Licensing
Content Licensing
Newswires & Feeds
Content Syndication
Digital Signage Services
Radio News Services
Premium Services
Premium
Intelligent Investor
Biotech Investor
NEW
Login
More
Latest News Videos
Free Content
RSS Feeds
Press Releases
Search
Contact Us
Business
Corp. News
Latest Headlines
Biotech
Investors
Stock Alerts
IPOs
M&A
Top Stories
Breaking News
Earnings
Canadian
UK
Wallstreet Events
Industry News
Technology
Software
Banking
Automotive
Energy
More
Corp. Calendars
Dividends
Stock Splits
Buybacks
Conference Calls
Earnings Calendar
Earnings Calendar
Pos Pre-announcements
Profit Warnings
Positive Surprise
Negative Surprise
Latest Earnings
FDA Calendars
Drug Approvals
Clinical Trial Calendar
Ratings Changes
Upgrades
Downgrades
Cov Initiations
Cov. Reiterated
Economy
US
Europe
Asia
Global
Economic Calendar
Economic Scorecard
Crypto
Cryptocurrency
Blockchain
Markets
Market News
Morning Mkt Analysis
US Commentary
European Commentary
Asian Commentary
Canadian Commentary
Indian Commentary
Commodities
Bonds
Currencies
Politics
US
World
White House
Elections
General News
Forex
FX Top Stories
Currency Analysis
Currency Alerts
Economic Calendar
Economic Scorecard
Health
Health News
Coronavirus
COVID-19 Calendar
Diet & Fitness
Cannabis
Kids Health
Men's Health
Women's Health
Cancer News
Drug Development
Mental Health
Slide Shows
Entertainment
Entertainment News
Top Stories
Music News
Pop
Rock
Classic Rock
Rap/Hip-Hop
Country
Alternative
Oldies
All Genre
Content Licensing
Newswires & Feeds
Content Syndication
Digital Signage Services
Radio News Services
Premium
Intelligent Investor
Biotech Investor
Login
More
Latest News Videos
Free Content
RSS Feeds
Press Releases
Search
Contact Us
Sanofi Sa (SNYNF)
Regeneron And Sanofi's Dupixent Gets EC Approval To Treat Children Aged 2-11 Years With CSU
4/13/2026 6:05:47 AM
Regeneron, Sanofi Secure EU Nod To Expand Dupixent Use In Young Children With CSU
4/13/2026 1:34:44 AM
Sanofi, Regeneron: EC Approves Dupixent For Pediatric Chronic Spontaneous Urticaria
4/13/2026 1:09:12 AM
Weekly Buzz: MGNX Resumes LINNET; GSK Wins China Nod; FDA Okays Waters; NBIX Snaps Up SLNO
4/10/2026 10:00:43 AM
Sanofi's Lunsekimig Shows Promise In Respiratory Diseases
4/7/2026 7:19:15 AM
Sanofi: Lunsekimig Meets Primary, Key Secondary Endpoints In Phase 2 Respiratory Studies
4/7/2026 1:26:08 AM
Sanofi’s Lunsekimig Shows Positive Phase 2 Results In Asthma And CRSwNP, While Missing Primary Endpoint In AD
4/7/2026 1:08:34 AM
Sanofi Receives EU Conditional Marketing Authorization For Rezurock In Chronic GVHD
3/31/2026 5:24:27 AM
Sanofi: European Commission Grants Conditional Marketing Authorisation For Rezurock
3/31/2026 1:28:06 AM
Sanofi: EU Approves Rezurock For Chronic Graft-versus-host Disease Treatment
3/31/2026 1:12:55 AM
Sanofi Gets EU Approval For Rezurock To Treat Chronic Graft-vs-host Disease
3/31/2026 1:12:54 AM
Biotech Stocks Facing FDA Decision In April 2026
3/30/2026 6:14:27 AM
Sanofi Reports Positive Phase 3 Results For Amlitelimab In Atopic Dermatitis
3/28/2026 12:31:54 PM
Weekly Buzz: CORT Wins FDA Nod In Cancer; MRK Acquires TERN; INSM Meets Trial Goals But VALN Misses
3/27/2026 9:42:17 AM
Sanofi: CHMP Adopts Positive Opinion Recommending Approval Of Sarclisa
3/27/2026 8:23:36 AM
Sanofi’s Sarclisa Subcutaneous On-Body Injector Formulation Recommended For EU Approval In Multiple Myeloma
3/27/2026 8:04:05 AM
Sanofi And Regeneron's Dupixent Approved In Japan For Bullous Pemphigoid
3/24/2026 7:14:07 AM
Sanofi: MHLW In Japan Approves Dupixent To Treat Moderate-to-severe Bullous Pemphigoid
3/24/2026 2:30:42 AM
Regeneron Pharma And Sanofi: Dupixent Approved In Japan To Treat Adults With Bullous Pemphigoid
3/24/2026 2:07:18 AM
Sanofi's Venglustat Gets FDA Breakthrough Therapy Designation For Type 3 Gaucher Disease
3/18/2026 8:58:40 AM
1
2
3
Next
»